Raymond S.L. Chang

6.2k total citations · 1 hit paper
114 papers, 4.7k citations indexed

About

Raymond S.L. Chang is a scholar working on Molecular Biology, Cellular and Molecular Neuroscience and Organic Chemistry. According to data from OpenAlex, Raymond S.L. Chang has authored 114 papers receiving a total of 4.7k indexed citations (citations by other indexed papers that have themselves been cited), including 72 papers in Molecular Biology, 52 papers in Cellular and Molecular Neuroscience and 27 papers in Organic Chemistry. Recurrent topics in Raymond S.L. Chang's work include Receptor Mechanisms and Signaling (52 papers), Neuropeptides and Animal Physiology (41 papers) and Renin-Angiotensin System Studies (25 papers). Raymond S.L. Chang is often cited by papers focused on Receptor Mechanisms and Signaling (52 papers), Neuropeptides and Animal Physiology (41 papers) and Renin-Angiotensin System Studies (25 papers). Raymond S.L. Chang collaborates with scholars based in United States, Japan and United Kingdom. Raymond S.L. Chang's co-authors include Victor J. Lotti, Solomon H. Snyder, Vinh T. Tran, Paul J. Kling, Roger Freidinger, Mark G. Bock, Deborah J. Cerino, Robert M. DiPardo, Tsing‐Bau Chen and James P. Springer and has published in prestigious journals such as Journal of the American Chemical Society, Circulation and Brain Research.

In The Last Decade

Raymond S.L. Chang

114 papers receiving 4.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists

1988 1.2k citations B. Evans, Kenneth E. Rittle et al. Journal of Medicinal Chemistry profile →

Peers

Countries citing papers authored by Raymond S.L. Chang

Since Specialization

Citations

This map shows the geographic impact of Raymond S.L. Chang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Raymond S.L. Chang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Raymond S.L. Chang more than expected).

Fields of papers citing papers by Raymond S.L. Chang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Raymond S.L. Chang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Raymond S.L. Chang. The network helps show where Raymond S.L. Chang may publish in the future.

Co-authorship network of co-authors of Raymond S.L. Chang

This figure shows the co-authorship network connecting the top 25 collaborators of Raymond S.L. Chang. A scholar is included among the top collaborators of Raymond S.L. Chang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Raymond S.L. Chang. Raymond S.L. Chang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	2-Aminobenzophenones as a Novel Class of Bradykinin B₁Receptor Antagonists 2008 ·Journal of Medicinal Chemistry ·Dai‐Shi Su, (unknown), (unknown), Bang-Lin Wan, Kathy Murphy, Duane R. Reiss, C. Meacham Harrell, (unknown), (unknown), Raymond S.L. Chang, Douglas J. Pettibone, (unknown), Cuyue Tang, Thomayant Prueksaritanont, Roger Freidinger, Mark G. Bock, Neville J. Anthony	13
2	Design, Synthesis, and In Vivo Efficacy of Glycine Transporter‐1 (GlyT1) Inhibitors Derived from a Series of [4‐Phenyl‐1‐(propylsulfonyl)piperidin‐4‐yl]methyl Benzamides 2006 ·ChemMedChem ·Craig W. Lindsley, Zhijian Zhao, William Leister, (unknown), Wei Lemaire, David L. Williams, Tsing‐Bau Chen, Raymond S.L. Chang, Maryann Burno, Marlene A. Jacobson, Cyrille Sur, Gene G. Kinney, Douglas J. Pettibone, Philip R. Tiller, Sheri Smith, Nancy N. Tsou, Mark E. Duggan, P. Jeffrey Conn, George D. Hartman	32
3	Generation and Characterization of a Human Bradykinin Receptor B1 Transgenic Rat as a Pharmacodynamic Model 2004 ·Journal of Pharmacology and Experimental Therapeutics ·J. Fred Hess, Richard W. Ransom, Zhizhen Zeng, Raymond S.L. Chang, Patricia J. Hey, (unknown), C. Meacham Harrell, (unknown), Tsing‐Bau Chen, Patricia Miller, Edward V. Lis, Duane R. Reiss, Raymond E. Gibson, (unknown), Robert M. DiPardo, Dai‐Shi Su, Mark G. Bock, Robert J. Gould, Douglas J. Pettibone	19
4	A Family of Highly Selective Allosteric Modulators of the Metabotropic Glutamate Receptor Subtype 5 2003 ·Molecular Pharmacology ·Julie A. O’Brien, Wei Lemaire, Tsing‐Bau Chen, Raymond S.L. Chang, Marlene A. Jacobson, Sookhee Ha, Craig W. Lindsley, Hervé Schaffhauser, Cyrille Sur, Douglas J. Pettibone, P. Jeffrey Conn, David L. Williams	170
5	Preparation and evaluation of 1,3-diaminocyclopentane-linked dihydropyrimidinone derivatives as selective α1a-receptor antagonists 2000 ·Bioorganic & Medicinal Chemistry Letters ·James C. Barrow, (unknown), Harold G. Selnick, Roger Freidinger, Raymond S.L. Chang, Stacey O’Malley, (unknown)	20
6	Selective α1a adrenergic receptor antagonists based on 4-aryl-3,4-dihydropyridine-2-ones 2000 ·Bioorganic & Medicinal Chemistry Letters ·Philippe G. Nantermet, James C. Barrow, Harold G. Selnick, Carl F. Homnick, Roger Freidinger, Raymond S.L. Chang, Stacey O’Malley, Duane R. Reiss, Theodore P. Broten, Richard W. Ransom, Douglas J. Pettibone, Timothy Olah, Carlos Forray	44
7	Phenylacetamides as selective α-1A adrenergic receptor antagonists 2000 ·Bioorganic & Medicinal Chemistry Letters ·Michael A. Patane, Robert M. DiPardo, (unknown), (unknown), Theodore P. Broten, Raymond S.L. Chang, Richard W. Ransom, Jerry Di Salvo, Dhanapalan Nagarathnam, Carlos Forray, Charles Gluchowski, Mark G. Bock	8
8	In vitro studies on L-771,688 (SNAP 6383), a new potent and selective α1A-adrenoceptor antagonist 2000 ·European Journal of Pharmacology ·Raymond S.L. Chang, (unknown), Stacey O’Malley, Douglas J. Pettibone, Jerry DiSalvo, Barbara Francis, Mark G. Bock, Roger Freidinger, Dhanapalan Nagarathnam, (unknown), Quanrong Shen, Bharat Lagu, T. G. Murali Dhar, Sriram Tyagarajan, Mohammad R. Marzabadi, Wai C. Wong, Charles Gluchowski, Carlos Forray	29
9	Characterization of the binding of [125I]L-735,286: A new nonpeptide angiotensin II AT1 receptor radioligand 1995 ·Life Sciences ·(unknown), (unknown), Raymond E. Gibson, H. Donald Burns, Raymond S.L. Chang	6
10	In vivo pharmacology of an angiotensin AT1 receptor antagonist with balanced affinity for angiotensin AT2 receptors 1995 ·European Journal of Pharmacology ·Salah D. Kivlighn, Gloria J. Zingaro, Robert A. Gabel, Theodore P. Broten, Raymond S.L. Chang, Debra L. Ondeyka, Nathan B. Mantlo, Raymond E. Gibson, William J. Greenlee, Peter K. S. Siegl	3
11	A Highly Potent, Orally Active Imidazo[4,5-b]pyridine Biphenyl Acylsulfonamide (MK-996; L-159,282): A New AT1-Selective Angiotensin II Receptor Antagonist 1994 ·Journal of Medicinal Chemistry ·Prasun K. Chakravarty, Elizabeth M. Naylor, (unknown), Raymond S.L. Chang, Tsing‐Bau Chen, Kristie A. Faust, Victor J. Lotti, Salah D. Kivlighn, Robert W. Gable	45
12	Non-peptide angiotensin II receptor antagonists. 1. Design, synthesis, and biological activity of N-substituted indoles and dihydroindoles 1993 ·Journal of Medicinal Chemistry ·(unknown), Scott W. Bagley, Raymond S.L. Chang, Victor J. Lotti, (unknown), Salah D. Kivlighn, Gloria J. Zingaro, Peter K. S. Siegl, Arthur A. Patchett, William J. Greenlee	24
13	Nonpeptide angiotensin II antagonists derived from 4H-1,2,4-triazoles and 3H-imidazo[1,2-b][1,2,4]triazoles 1993 ·Journal of Medicinal Chemistry ·Wallace T. Ashton, (unknown), Linda Chang, Steven M. Hutchins, (unknown), Malcolm MacCoss, Raymond S.L. Chang, Victor J. Lotti, Kristie A. Faust	40
14	Triazolinones as nonpeptide angiotensin II antagonists. 1. Synthesis and evaluation of potent 2,4,5-trisubstituted triazolinones 1993 ·Journal of Medicinal Chemistry ·Linda Chang, Wallace T. Ashton, (unknown), (unknown), Malcolm MacCoss, (unknown), Raymond S.L. Chang, Victor J. Lotti, Kristie A. Faust	20
15	A potent, orally active, balanced affinity angiotensin II AT1 antagonist and AT2 binding inhibitor 1993 ·Journal of Medicinal Chemistry ·Stephen E. de Laszlo, (unknown), William J. Greenlee, Arthur A. Patchett, Raymond S.L. Chang, Victor J. Lotti, (unknown), (unknown), (unknown)	102
16	Novel glutamic acid-derived cholecystokinin receptor ligands 1990 ·Journal of Medicinal Chemistry ·Roger Freidinger, Willie L. Whitter, (unknown), M. K. HOLLOWAY, Raymond S.L. Chang, Victor J. Lotti	18
17	A new potent and selective non-peptide gastrin antagonist and brain cholecystokinin receptor (CCK-B) ligand: L-365,260 1989 ·European Journal of Pharmacology ·Victor J. Lotti, Raymond S.L. Chang	347
18	Cholecystokinin antagonists. Synthesis and biological evaluation of 3-substituted benzolactams 1989 ·Journal of Medicinal Chemistry ·William H. Parsons, Arthur A. Patchett, M. K. HOLLOWAY, Graham Smith, (unknown), Victor J. Lotti, Raymond S.L. Chang	19
19	Specific [3H]propionyl-neuropeptide Y (NPY) binding in rabbit aortic membranes: Comparisons with binding in rat brain and biological responses in rat vas deferens 1988 ·Biochemical and Biophysical Research Communications ·Raymond S.L. Chang, Victor J. Lotti, Tsing‐Bau Chen	42
20	Cholecystokinin antagonists. Synthesis and biological evaluation of 4-substituted 4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepines 1988 ·Journal of Medicinal Chemistry ·Mark G. Bock, Robert M. DiPardo, B. Evans, Kenneth E. Rittle, Daniel F. Veber, Roger Freidinger, Raymond S.L. Chang, Victor J. Lotti	16

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact